Open access
Open access
Powered by Google Translator Translator

Rheumatology

RCT: Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders.

22 Jul, 2021 | 10:42h | UTC

Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial – The Lancet

Commentaries: Optimising treatment for patients with rotator cuff disorders – The Lancet (free registration required)

 

Commentary on Twitter (thread – click for more)

 


Sacroiliac joint dysfunction: pathophysiology, diagnosis, and treatment.

21 Jul, 2021 | 10:26h | UTC

Sacroiliac joint dysfunction: pathophysiology, diagnosis, and treatment – European Spine Journal

 


Sarcoidosis: A clinical overview from symptoms to diagnosis.

15 Jul, 2021 | 08:58h | UTC

Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis – Cells

 


2021 ACR Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.

13 Jul, 2021 | 09:41h | UTC

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis – Arthritis & Rheumatology

 


2021 ACR Guideline for the Management of Polyarteritis Nodosa.

13 Jul, 2021 | 09:37h | UTC

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa – Arthritis & Rheumatology

 


2021 ACR Guideline for the Management of ANCA–Associated Vasculitis.

9 Jul, 2021 | 10:09h | UTC

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis – Arthritis & Rheumatology

 


M-A: Little benefit from muscle relaxants for adults with non-specific low back pain.

9 Jul, 2021 | 10:02h | UTC

Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis – The BMJ

Commentary: New analysis finds muscle relaxant drugs to be largely ineffective for low back pain – News Medical

Related studies: M-A: Effectiveness of treatments for acute and subacute mechanical non-specific low back pain AND RCT: Little benefit from osteopathic manipulative treatment on activity limitations in patients with nonspecific subacute and chronic low back pain AND M-A: Little benefit from antidepressants for low back pain AND Meta-analysis: Little benefit from antidepressants for the treatment of back pain and osteoarthritis AND ACP/AAFP Guideline: Nonpharmacologic and pharmacologic management of acute pain from non–low back, musculoskeletal injuries in adults

 

Commentaries on Twitter

 


Adult-Onset Still’s Disease: Clinical Aspects and Therapeutic Approach.

9 Jul, 2021 | 09:47h | UTC

Adult-Onset Still’s Disease: Clinical Aspects and Therapeutic Approach – Journal of Clinical Medicine

 


Guideline | Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring.

6 Jul, 2021 | 10:03h | UTC

Executive summary: Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring – Royal College of Ophthalmologists

Full Guideline: The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary

See also: The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary – Eye

 


M-A: The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis.

6 Jul, 2021 | 09:54h | UTC

The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis – Rheumatology

 


Consensus-based recommendations for the management of juvenile systemic sclerosis

2 Jul, 2021 | 11:08h | UTC

Consensus-based recommendations for the management of juvenile systemic sclerosis – Rheumatology

 


Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.

22 Jun, 2021 | 10:04h | UTC

Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection – Canadian Medical Association Journal

Commentary: COVID-19-related multisystem inflammatory syndrome in adults: Rare but possible – Canadian Medical Association Journal

 


2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

10 Jun, 2021 | 09:37h | UTC

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis – Arthritis Care & Research

Commentary: The 2021 Treatment Guidelines for Rheumatoid Arthritis – Rheumatology Network

 


M-A: Effectiveness of telerehabilitation in physical therapist practice.

10 Jun, 2021 | 09:29h | UTC

Effectiveness of Telerehabilitation in Physical Therapist Practice: An Umbrella and Mapping Review With Meta–Meta-Analysis – Physical Therapy & Rehabilitation Journal

 


RCT: Among patients with ANCA-associated vasculitis without severe glomerulonephritis or alveolar hemorrhage treated with Rituximab, a reduced-dose glucocorticoids regimen (prednisolone 0.5 mg/kg/d) was noninferior to a high-dose glucocorticoid regimen (prednisolone 1 mg/kg/d) for the induction of disease remission.

4 Jun, 2021 | 10:25h | UTC

Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial – JAMA

 


ANCA-Associated Vasculitis: An Update.

4 Jun, 2021 | 10:23h | UTC

ANCA-Associated Vasculitis: An Update – Journal of Clinical Medicine

 


Podcast | Osteoporosis in Primary Care.

1 Jun, 2021 | 08:06h | UTC

#277 Bone Up on Osteoporosis in Primary Care with Dr. Carolyn Crandall – The Curbsiders

 


EULAR recommendations for intra-articular therapies.

28 May, 2021 | 08:16h | UTC

EULAR recommendations for intra-articular therapies – Annals of Rheumatic Diseases

 


Methotrexate reduces immune response to mRNA COVID-19 vaccine in patients with immune-mediated inflammatory disease.

26 May, 2021 | 08:38h | UTC

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease – Annals of Rheumatic Diseases

Commentary: Methotrexate users have a reduced immune response to mRNA COVID-19 vaccine – BMJ

 


Large cohort study confirms the renal toxicities of anti-inflammatories, suggesting Ibuprofen may be the safest option among them.

19 May, 2021 | 08:28h | UTC

Comparative Risks of Nonsteroidal Anti-Inflammatory Drugs on CKD – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)

Commentary: Study: Ibuprofen Found Safest NSAID for the Kidney – MPR

 

Commentary on Twitter

 


2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

13 May, 2021 | 05:49h | UTC

2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis – Annals of Rheumatic Diseases

Commentary: EULAR issues recommendations on self-management strategies for inflammatory arthritis – MedwireNews

 


Editorial | “Peeling off musculoskeletal labels: sticks and stones may break my bones, but diagnostic labels can hamstring me forever”

11 May, 2021 | 08:59h | UTC

Peeling off musculoskeletal labels: sticks and stones may break my bones, but diagnostic labels can hamstring me forever – British Journal of Sports Medicine

 

Commentary on Twitter

 


RCT: Efficacy and safety of voclosporin for lupus nephritis – voclosporin + MMF + low dose corticosteroids achieved complete renal response at week 52 more often than MMF + low dose corticosteroids alone (41% vs. 23%).

10 May, 2021 | 00:48h | UTC

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 


RCT: Therapeutic drug monitoring during infliximab induction does not improve disease remission in patients with chronic immune-mediated inflammatory diseases

7 May, 2021 | 08:27h | UTC

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (free for a limited period)

Commentary: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly

 

Commentary on Twitter

 


RCT: Among patients with rheumatoid arthritis in remission, tapering conventional DMARDs using half-dose resulted in disease flares in 25% of patients compared with 6% of patients in the stable-dose group.

7 May, 2021 | 08:26h | UTC

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (free for a limited period)

Commentary: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly

 


Stay Updated in Your Specialty

No spam, just news.